Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 3/20 | 1.00 |
| ▸ | ATM | Q13315 | 3/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21513069 | 1.00 | PRKDC (1.00) | PRKDCATMPIK3CASCN9APIK3CD | |
| Hydrochloric Acid SCHEMBL29629170 | 0.99 | PRKDC (0.99) | PRKDCATMPIK3CASCN9APIK3CD | |
| SCHEMBL22941911 | 0.95 | PRKDC (0.90) | PRKDCATMPIK3CASCN9APIK3CD | |
| SCHEMBL29629176 | 0.95 | PRKDC (0.90) | PRKDCATMPIK3CASCN9APIK3CD | |
| SCHEMBL22941899 | 0.94 | PRKDC (0.89) | PRKDCATMPIK3CDPIK3CGKCNH2 | |
| SCHEMBL29661254 | 0.94 | PRKDC (0.89) | PRKDCATMPIK3CDPIK3CGKCNH2 | |
| Hydrochloric Acid SCHEMBL29629181 | 0.94 | PRKDC (0.89) | PRKDCATMPIK3CAPIK3CDPIK3CB | |
| SCHEMBL21513816 | 0.94 | PRKDC (0.88) | PRKDCATMKCNH2 | |
| Hydrochloric Acid SCHEMBL29735635 | 0.94 | PRKDC (0.88) | PRKDCATMPIK3CDPIK3CGKCNH2 | |
| SCHEMBL21513826 | 0.94 | PRKDC (0.88) | PRKDCATMPIK3CASCN9APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003345-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20220142995-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142995-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | PRKDC 67/4885ATM 1/4885PIK3CA 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.